Publications

452 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Guideline for economic evaluations in healthcare (2024 version)

    More often considerations are being made about the cost-effectiveness of healthcare intervention what should be reimbursed from ...

    Report | 16-01-2024

  2. Advice - Adjustment of reimbursement conditions for lenacapavir (Sunlenca®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to adjust the conditions of ...

    Report | 20-12-2023

  3. Advice - Extension of reimbursement conditions for risdiplam (Evrysdi®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to also reimburse risdiplam ...

    Report | 20-12-2023

  4. Package advice on the lock procedure medicinal product abemaciclib (Verzenios®) for the treatment of breast cancer

    The National Health Care Institute has assessed whether the medicinal product abemaciclib (Verzenios®) can be reimbursed as an ...

    Report | 13-12-2023

  5. GVS advice tezepelumab (Tezspire®) for the treatment of patients 12 years and older with severe asthma

    The National Health Care Institute has assessed whether tezepelumab (Tezspire®) can be included in the Medicine Reimbursement ...

    Report | 12-12-2023

  6. Package advice for the lock procedure medicinal product ravulizumab (Ultomiris®) for the treatment of adult patients with myasthenia gravis

    The National Health Care Institute has assessed whether the medicinal product ravulizumab (Ultomiris®) can be reimbursed from the ...

    Report | 12-12-2023

  7. GVS advice empagliflozin (Jardiance®) expansion List 2 conditions for chronic kidney disease

    The National Health Care Institute has assessed whether the reimbursement conditions for empagliflozin (Jardiance®) can be ...

    Report | 07-12-2023

  8. Final report – Case study phase ROR DGM

    The Dutch National Health Care Institute presents its vision on data availability in healthcare, based on 4 completed case ...

    Report | 30-11-2023

  9. GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

    The National Health Care Institute has assessed whether latanoprost in combination with netarsudil (Roclanda®) can be included in ...

    Report | 22-11-2023

  10. Package advice lock procedure product emicizumab (Hemlibra®) for the treatment of moderate haemophilia A

    The National Health Care Institute has assessed whether emicizumab (Hemlibra®) can be reimbursed from the basic health care ...

    Report | 16-11-2023